0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > MIF

MIF

Brief Information

Name:Macrophage migration inhibitory factor
Target Synonym:Glycosylation-inhibiting factor,L-dopachrome isomerase,MIF,Macrophage Migration Inhibitory Factor,Macrophage Migration Inhibitory Factor (Glycosylation-Inhibiting Factor),GLIF,MMIF,EC:5.3.2.1,GIF,EC 5.3.3.12,EC 5.3.2.1,Macrophage Migration-Inhibitory Fact
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
MIF-H82E7 Human Biotinylated Human MIF Protein, His,Avitag™
MIF-H82E7-structure
MIF-H82E7-sds

Synonym Name

MIF,GLIF,MMIF,GIF

Background

Macrophage migration inhibitory factor(MIF) is also known as Glycosylation-inhibiting factor(GIF), L-dopachrome isomerase, L-dopachrome tautomerase, Phenylpyruvate tautomerase. Interacts with CXCR2 extracellular domain, CD74 extracellular domain, COPS5 and BNIPL.  The expression of MIF at sites of inflammation suggests a role as mediator in regulating the function of macrophages in host defense. Counteracts the anti-inflammatory activity of glucocorticoids. Has phenylpyruvate tautomerase and dopachrome tautomerase activity (in vitro), but the physiological substrate is not known. It is not clear whether the tautomerase activity has any physiological relevance, and whether it is important for cytokine activity.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Ibudilast AV-411; KC-404; MN-166 Approved Ketas, Pinatos, Eyevinal Japan Asthma; Multiple Sclerosis; Neuralgia Kyorin Pharmaceutical Co Ltd 1989-01-01 Diabetic Neuropathies; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis; Pneumonia, Viral; Asthma; Neuralgia; Amyotrophic Lateral Sclerosis Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Imalumab BAX-69; BAX-069 Phase 2 Clinical Cytokine Pharmasciences Ovarian Neoplasms; Lupus Nephritis; Ascites; Colorectal Neoplasms Details
IPG-1094 IPG-1094 Phase 1 Clinical Hematologic Neoplasms; Solid tumours; Multiple Sclerosis; Psoriasis Details

This web search service is supported by Google Inc.

totop